Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence
NCT07799519
Summary
Atrial fibrillation (AF) is a common heart rhythm disorder associated with stroke, heart failure, and increased mortality. Catheter ablation with pulmonary vein isolation (PVI) is an effective rhythm-control strategy, but 20-30% of patients experience AF recurrence within one year. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist with anti-inflammatory, antifibrotic, and metabolic effects, was associated with a lower incidence of AF in prior large trials, and preclinical studies suggest it promotes "browning" of adipose tissue and improves epicardial adipose tissue (EAT) characteristics. This single-center, randomized, investigator-blinded pilot trial will enroll 40 patients undergoing first-time catheter ablation for AF. After successful PVI, participants will be randomized 1:1 to receive finerenone or usual care for 12 months. The primary endpoint is AF recurrence (any atrial arrhythmia episode lasting 30 seconds or longer) after a 90-day blanking period, within 12 months post-ablation. Mechanistic endpoints include EAT remodeling assessed by cardiac computed tomography and echocardiography, and circulating uncoupling protein-1 (UCP1) levels as a biomarker of adipose tissue browning. The investigators hypothesize that finerenone will lower AF recurrence after ablation, partly through modulation of EAT function.
Eligibility
Inclusion Criteria: * Age 18-80 years * Atrial fibrillation scheduled for first-time catheter ablation (pulmonary vein isolation) * Estimated glomerular filtration rate (eGFR) \>=25 mL/min/1.73 m2 * Serum potassium \<=5.0 mmol/L Exclusion Criteria: * History of prior catheter-based or surgical pulmonary vein isolation * Current use of other mineralocorticoid receptor antagonists (MRAs) * Severe renal impairment (eGFR \<25 mL/min/1.73 m2) * Serum potassium \>5.0 mmol/L * Severe liver disease (Child-Pugh class C) * Known hypersensitivity to the investigational drug * Contraindications to the investigational drug, such as concomitant use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital) * Active cancer or recent chemotherapy * Women who are pregnant, breastfeeding, or planning to become pregnant during the study period
Conditions2
Interventions1
Related trials
- Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease — Second Affiliated Hospital of Soochow University
- Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes — Steno Diabetes Center Copenhagen
- Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease — Chinese University of Hong Kong
- A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients — Colorado Prevention Center
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) — Colorado Prevention Center
- A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists — Colorado Prevention Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07799519